529944509	529944509	CD	B-NP	O
|	|	NN	I-NP	O
SH	SH	NN	I-NP	O
|	|	NN	I-NP	O
81468164	81468164	CD	I-NP	O
|	|	NN	I-NP	O
|	|	NN	I-NP	O
7616078	7616078	CD	B-NP	O
|	|	CC	I-NP	O
10/30/2005	10/30/2005	CD	I-NP	O
12	12	CD	I-NP	O
:	:	:	O	O
00	00	CD	B-NP	O
:	:	:	O	O
00	00	CD	B-NP	O
AM	AM	VBP	B-VP	O
|	|	JJ	B-NP	B-protein
RESPIRATORY	RESPIRATORY	NNP	I-NP	I-protein
INSUFFICIENCY	INSUFFICIENCY	NNP	I-NP	I-protein
|	|	NNP	I-NP	I-protein
Signed	Signed	NNP	I-NP	I-protein
|	|	NNP	I-NP	I-protein
DIS	DIS	NNP	I-NP	I-protein
|	|	NNP	I-NP	I-protein
Admission	Admission	NNP	I-NP	O
Date	Date	NNP	I-NP	O
:	:	:	O	O
4/25/2005	4/25/2005	CD	B-NP	O
Report	Report	NNP	I-NP	O
Status	Status	NNP	I-NP	O
:	:	:	O	O
Signed	Signed	NNP	B-NP	O
Discharge	Discharge	NNP	I-NP	O
Date	Date	NNP	I-NP	O
:	:	:	O	O
11/8/2005	11/8/2005	CD	B-NP	O
ATTENDING	ATTENDING	NN	I-NP	O
:	:	:	O	O
MEADERS	MEADERS	NNS	B-NP	O
,	,	,	O	O
DONNY	DONNY	NNP	B-NP	O
MD	MD	NNP	I-NP	O
CONSULTS	CONSULTS	NNS	I-NP	O
:	:	:	O	O
Consults	Consult	NNS	B-NP	O
for	for	IN	B-PP	O
this	this	DT	B-NP	O
patient	patient	NN	I-NP	O
included	include	VBD	B-VP	O
Urology	Urology	NNP	B-NP	O
and	and	CC	I-NP	O
Cardiology	Cardiology	NNP	I-NP	O
.	.	.	O	O

PROCEDURES	PROCEDURES	NNS	B-NP	O
:	:	:	O	O
Procedures	Procedure	NNS	B-NP	O
for	for	IN	B-PP	O
this	this	DT	B-NP	O
patient	patient	NN	I-NP	O
included	include	VBD	B-VP	O
a	a	DT	B-NP	O
urological	urological	JJ	I-NP	O
procedure	procedure	NN	I-NP	O
with	with	IN	B-PP	O
placement	placement	NN	B-NP	O
of	of	IN	B-PP	O
a	a	DT	B-NP	O
ureteral	ureteral	JJ	I-NP	O
stent	stent	NN	I-NP	O
and	and	CC	O	O
subsequent	subsequent	JJ	B-NP	O
removal	removal	NN	I-NP	O
of	of	IN	B-PP	O
the	the	DT	B-NP	O
ureteral	ureteral	JJ	I-NP	O
stent	stent	NN	I-NP	O
.	.	.	O	O

MEDICATIONS	MEDICATIONS	NNS	B-NP	O
:	:	:	O	O
Her	Her	PRP$	B-NP	O
medications	medication	NNS	I-NP	O
on	on	IN	B-PP	O
admission	admission	NN	B-NP	O
included	include	VBD	B-VP	O
Lasix	Lasix	NNP	B-NP	O
20	20	CD	I-NP	O
mg	mg	NN	I-NP	O
b.i.d.	b.i.d.	RB	B-ADVP	O
,	,	,	O	O
OxyContin	OxyContin	NN	B-NP	O
90	90	CD	I-NP	O
b.i.d.	b.i.d.	NN	I-NP	O
and	and	CC	I-NP	O
40	40	CD	I-NP	O
q.	q.	NN	I-NP	O
2	2	CD	B-NP	O
p.m.	p.m.	NN	I-NP	O
,	,	,	O	O
lisinopril	lisinopril	NN	B-NP	O
40	40	CD	I-NP	O
daily	daily	RB	B-ADVP	O
,	,	,	O	O
Norvasc	Norvasc	NNP	B-NP	O
5	5	CD	I-NP	O
b.i.d.	b.i.d.	NN	I-NP	O
,	,	,	O	O
digoxin	digoxin	NN	B-NP	O
0.125	0.125	CD	I-NP	O
b.i.d.	b.i.d.	NN	I-NP	O
,	,	,	O	O
Levoxyl	Levoxyl	NNP	B-NP	O
88	88	CD	I-NP	O
mcg	mcg	NN	I-NP	O
,	,	,	O	O
Ativan	Ativan	NNP	B-NP	O
0.5	0.5	CD	I-NP	O
at	at	IN	B-PP	O
bedtime	bedtime	NN	B-NP	O
,	,	,	O	O
Niferex	Niferex	NNP	B-NP	O
150	150	CD	I-NP	O
b.i.d.	b.i.d.	NNP	I-NP	O
,	,	,	O	O
Colace	Colace	NNP	B-NP	O
b.i.d.	b.i.d.	NNP	I-NP	O
,	,	,	O	O
lactulose	lactulose	RB	B-NP	O
50	50	CD	I-NP	O
daily	daily	RB	I-NP	O
,	,	,	O	O
Faslodex	Faslodex	NNP	B-NP	O
250	250	CD	I-NP	O
IM	IM	NNP	I-NP	O
q.	q.	NN	I-NP	O
month	month	NN	I-NP	O
,	,	,	O	O
Coumadin	Coumadin	NN	B-NP	O
5	5	CD	I-NP	O
daily	daily	NN	I-NP	O
,	,	,	O	O
Zometa	Zometa	NN	B-NP	O
q.	q.	NN	I-NP	O
month	month	NN	I-NP	O
,	,	,	O	O
Fosamax	Fosamax	NN	B-NP	B-protein
70	70	CD	I-NP	I-protein
q.	q.	NN	I-NP	I-protein
week	week	NN	I-NP	I-protein
,	,	,	O	O
and	and	CC	O	O
exemestane	exemestane	NN	B-NP	O
25	25	CD	I-NP	O
mg	mg	NN	I-NP	O
po	po	RB	B-ADVP	O
daily	daily	RB	I-ADVP	O
.	.	.	O	O

ALLERGIES	ALLERGIES	NNS	B-NP	O
:	:	:	O	O
Her	Her	PRP$	B-NP	O
allergies	allergy	NNS	I-NP	O
included	include	VBD	B-VP	O
penicillin	penicillin	NN	B-NP	B-protein
,	,	,	O	O
which	which	WDT	B-NP	O
resulted	result	VBD	B-VP	O
in	in	IN	B-PP	O
pruritus	pruritus	NN	B-NP	O
and	and	CC	O	O
a	a	DT	B-NP	O
rash	rash	NN	I-NP	O
.	.	.	O	O

HISTORY	HISTORY	NN	B-NP	O
OF	OF	IN	B-PP	O
PRESENT	PRESENT	JJ	B-NP	O
ILLNESS	ILLNESS	NN	I-NP	O
:	:	:	O	O
This	This	DT	B-NP	O
is	be	VBZ	B-VP	O
a	a	DT	B-NP	O
75-year-old	75-year-old	JJ	I-NP	O
woman	woman	NN	I-NP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
history	history	NN	I-NP	O
of	of	IN	B-PP	O
rheumatic	rheumatic	JJ	B-NP	O
heart	heart	NN	I-NP	O
disease	disease	NN	I-NP	O
,	,	,	O	O
status	status	NN	B-NP	O
post	post	NN	I-NP	O
St.	St.	NNP	I-NP	O
Jude	Jude	NNP	I-NP	O
's	's	POS	B-NP	O
mitral	mitral	JJ	I-NP	O
valve	valve	NN	I-NP	O
repair	repair	NN	I-NP	O
as	as	RB	B-CONJP	O
well	well	RB	I-CONJP	O
as	as	IN	I-CONJP	O
AV	AV	NN	B-NP	O
and	and	CC	I-NP	O
TV	TV	NN	I-NP	O
repair	repair	NN	I-NP	O
who	who	WP	B-NP	O
has	have	VBZ	B-VP	O
CHF	CHF	NN	B-NP	B-protein
at	at	IN	B-PP	O
baseline	baseline	NN	B-NP	O
with	with	IN	B-PP	O
an	an	DT	B-NP	O
EF	EF	NN	I-NP	O
of	of	IN	B-PP	O
40	40	CD	B-NP	O
%	%	NN	I-NP	O
to	to	TO	B-PP	O
45	45	CD	B-NP	O
%	%	NN	I-NP	O
as	as	RB	B-CONJP	O
well	well	RB	I-CONJP	O
as	as	IN	I-CONJP	O
metastatic	metastatic	JJ	B-NP	O
breast	breast	NN	I-NP	O
cancer	cancer	NN	I-NP	O
and	and	CC	O	O
a	a	DT	B-NP	O
recent	recent	JJ	I-NP	O
history	history	NN	I-NP	O
of	of	IN	B-PP	O
hydronephrosis	hydronephrosis	NN	B-NP	O
who	who	WP	B-NP	O
initially	initially	RB	B-ADVP	O
presented	present	VBD	B-VP	O
with	with	IN	B-PP	O
chest	chest	NN	B-NP	O
discomfort	discomfort	NN	I-NP	O
with	with	IN	B-PP	O
exertion	exertion	NN	B-NP	O
that	that	WDT	B-NP	O
resolved	resolve	VBD	B-VP	O
with	with	IN	B-PP	O
rest	rest	NN	B-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
chest	chest	NN	I-NP	O
pain	pain	NN	I-NP	O
started	start	VBD	B-VP	O
five	five	CD	B-NP	O
days	day	NNS	I-NP	O
prior	prior	RB	B-ADVP	O
to	to	TO	B-PP	O
admission	admission	NN	B-NP	O
,	,	,	O	O
which	which	WDT	B-NP	O
is	be	VBZ	B-VP	O
described	describe	VBN	I-VP	O
as	as	IN	B-PP	O
a	a	DT	B-NP	O
7	7	CD	I-NP	O
or	or	CC	I-NP	O
8	8	CD	I-NP	O
out	out	IN	B-PP	O
of	of	IN	B-PP	O
10	10	CD	B-NP	O
associated	associate	VBN	B-VP	O
with	with	IN	B-PP	O
nausea	nausea	NN	B-NP	O
and	and	CC	I-NP	O
shortness	shortness	NN	I-NP	O
of	of	IN	B-PP	O
breath	breath	NN	B-NP	O
,	,	,	O	O
but	but	CC	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
denied	deny	VBD	B-VP	O
any	any	DT	B-NP	O
radiation	radiation	NN	I-NP	O
of	of	IN	B-PP	O
the	the	DT	B-NP	O
pain	pain	NN	I-NP	O
,	,	,	O	O
any	any	DT	B-NP	O
vomiting	vomiting	NN	I-NP	O
,	,	,	O	O
or	or	CC	O	O
any	any	DT	B-NP	O
diaphoresis	diaphoresis	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
also	also	RB	B-ADVP	O
said	say	VBD	B-VP	O
that	that	IN	B-SBAR	O
she	she	PRP	B-NP	O
had	have	VBD	B-VP	O
PND	PND	NN	B-NP	O
and	and	CC	I-NP	O
orthopnea	orthopnea	NN	I-NP	O
at	at	IN	B-PP	O
baseline	baseline	NN	B-NP	O
and	and	CC	O	O
she	she	PRP	B-NP	O
had	have	VBD	B-VP	O
recently	recently	RB	I-VP	O
increased	increase	VBN	I-VP	O
her	her	PRP$	B-NP	O
number	number	NN	I-NP	O
of	of	IN	B-PP	O
pillows	pillow	NNS	B-NP	O
that	that	IN	B-SBAR	O
she	she	PRP	B-NP	O
sleeps	sleep	VBZ	B-VP	O
on	on	IN	B-PP	O
,	,	,	O	O
from	from	IN	B-PP	O
two	two	CD	B-NP	O
to	to	TO	B-PP	O
three	three	CD	B-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
weight	weight	NN	I-NP	O
had	have	VBD	B-VP	O
been	be	VBN	I-VP	O
stable	stable	JJ	B-ADJP	O
with	with	IN	B-PP	O
no	no	DT	B-NP	O
change	change	NN	I-NP	O
in	in	IN	B-PP	O
diet	diet	NN	B-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
ruled	rule	VBD	B-VP	O
out	out	RP	B-PRT	O
for	for	IN	B-PP	O
an	an	DT	B-NP	O
MI	MI	NN	I-NP	O
;	;	:	O	O
however	however	RB	B-ADVP	O
,	,	,	O	O
given	give	VBN	B-PP	O
her	her	PRP$	B-NP	O
hydronephrosis	hydronephrosis	NN	I-NP	O
,	,	,	O	O
thought	think	VBN	B-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
secondary	secondary	JJ	B-ADJP	O
to	to	TO	B-PP	O
her	her	PRP$	B-NP	O
metastatic	metastatic	JJ	I-NP	O
cancer	cancer	NN	I-NP	O
and	and	CC	O	O
her	her	PRP$	B-NP	O
rise	rise	NN	I-NP	O
in	in	IN	B-PP	O
creatinine	creatinine	NN	B-NP	O
,	,	,	O	O
it	it	PRP	B-NP	O
was	be	VBD	B-VP	O
decided	decide	VBN	I-VP	O
to	to	TO	I-VP	O
place	place	VB	I-VP	O
a	a	DT	B-NP	O
ureteral	ureteral	JJ	I-NP	O
stent	stent	NN	I-NP	O
,	,	,	O	O
which	which	WDT	B-NP	O
was	be	VBD	B-VP	O
done	do	VBN	I-VP	O
by	by	IN	B-PP	O
the	the	DT	B-NP	O
Urology	Urology	NNP	I-NP	O
Service	Service	NNP	I-NP	O
.	.	.	O	O

However	However	RB	B-ADVP	O
,	,	,	O	O
after	after	IN	B-PP	O
the	the	DT	B-NP	O
stent	stent	NN	I-NP	O
was	be	VBD	B-VP	O
placed	place	VBN	I-VP	O
,	,	,	O	O
she	she	PRP	B-NP	O
developed	develop	VBD	B-VP	O
severe	severe	JJ	B-NP	O
pain	pain	NN	I-NP	O
,	,	,	O	O
fever	fever	NN	B-NP	O
,	,	,	O	O
and	and	CC	O	O
increased	increase	VBN	B-NP	O
white	white	JJ	I-NP	O
blood	blood	NN	I-NP	O
cell	cell	NN	I-NP	O
count	count	NN	I-NP	O
.	.	.	O	O

Although	Although	IN	B-SBAR	O
the	the	DT	B-NP	O
fever	fever	NN	I-NP	O
and	and	CC	O	O
white	white	JJ	B-NP	O
blood	blood	NN	I-NP	O
cell	cell	NN	I-NP	O
count	count	NN	I-NP	O
resolved	resolve	VBN	B-VP	O
,	,	,	O	O
she	she	PRP	B-NP	O
continued	continue	VBD	B-VP	O
to	to	TO	I-VP	O
feel	feel	VB	I-VP	O
pain	pain	NN	B-NP	O
,	,	,	O	O
and	and	CC	O	O
it	it	PRP	B-NP	O
was	be	VBD	B-VP	O
decided	decide	VBN	I-VP	O
to	to	TO	I-VP	O
remove	remove	VB	I-VP	O
the	the	DT	B-NP	O
ureteral	ureteral	JJ	I-NP	O
stent	stent	NN	I-NP	O
since	since	IN	B-SBAR	O
it	it	PRP	B-NP	O
was	be	VBD	B-VP	O
not	not	RB	I-VP	O
decreasing	decrease	VBG	I-VP	O
her	her	PRP$	B-NP	O
creatinine	creatinine	NN	I-NP	O
.	.	.	O	O

PHYSICAL	PHYSICAL	JJ	B-NP	O
EXAMINATION	EXAMINATION	NN	I-NP	O
:	:	:	O	O
Her	Her	PRP$	B-NP	O
admission	admission	NN	I-NP	O
physical	physical	JJ	I-NP	O
exam	exam	NN	I-NP	O
was	be	VBD	B-VP	O
notable	notable	JJ	B-ADJP	O
for	for	IN	B-PP	O
a	a	DT	B-NP	O
blood	blood	NN	I-NP	O
pressure	pressure	NN	I-NP	O
of	of	IN	B-PP	O
168/94	168/94	CD	B-NP	O
.	.	.	O	O

Other	Other	JJ	B-NP	O
vitals	vital	NNS	I-NP	O
included	include	VBD	B-VP	O
a	a	DT	B-NP	O
temperature	temperature	NN	I-NP	B-protein
97.2	97.2	CD	I-NP	I-protein
,	,	,	O	O
pulse	pulse	NN	B-NP	O
69	69	CD	I-NP	O
,	,	,	O	O
respiratory	respiratory	JJ	B-NP	O
rate	rate	NN	I-NP	O
16	16	CD	I-NP	O
,	,	,	O	O
and	and	CC	O	O
saturating	saturate	VBG	B-VP	O
98	98	CD	B-NP	O
%	%	NN	I-NP	O
on	on	IN	B-PP	O
room	room	NN	B-NP	O
air	air	NN	I-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
JVP	JVP	NN	I-NP	B-protein
was	be	VBD	B-VP	I-protein
9	9	CD	B-NP	I-protein
.	.	.	O	O

She	She	PRP	B-NP	O
had	have	VBD	B-VP	O
left	leave	VBN	I-VP	O
lower	low	JJR	B-NP	O
lung	lung	NN	I-NP	O
crackles	crackle	NNS	I-NP	O
,	,	,	O	O
otherwise	otherwise	RB	B-ADJP	O
clear	clear	JJ	I-ADJP	O
.	.	.	O	O

She	She	PRP	B-NP	O
has	have	VBZ	B-VP	O
a	a	DT	B-NP	O
very	very	RB	I-NP	O
loud	loud	JJ	I-NP	O
ejection	ejection	NN	I-NP	O
murmur	murmur	NN	I-NP	O
,	,	,	O	O
loud	loud	JJ	B-NP	O
S1	S1	NN	I-NP	B-protein
and	and	CC	O	O
S2	S2	NN	B-NP	B-protein
.	.	.	O	O

She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
in	in	IN	B-PP	O
atrial	atrial	JJ	B-NP	O
fibrillation	fibrillation	NN	I-NP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
irregularly	irregularly	RB	I-NP	O
irregular	irregular	JJ	I-NP	O
heart	heart	NN	I-NP	O
rate	rate	NN	I-NP	O
with	with	IN	B-PP	O
no	no	DT	B-NP	O
rub	rub	NN	I-NP	B-protein
and	and	CC	O	O
she	she	PRP	B-NP	O
had	have	VBD	B-VP	O
a	a	DT	B-NP	O
1	1	CD	I-NP	O
to	to	TO	I-NP	O
2	2	CD	I-NP	O
+	+	SYM	I-NP	O
edema	edema	NN	I-NP	O
bilaterally	bilaterally	RB	B-ADVP	O
and	and	CC	O	O
she	she	PRP	B-NP	O
was	be	VBD	B-VP	O
trace	trace	NN	B-NP	O
guaiac	guaiac	NN	I-NP	O
positive	positive	JJ	B-ADJP	O
.	.	.	O	O

PROBLEM	PROBLEM	NN	B-NP	O
LIST	LIST	NN	I-NP	O
BY	BY	NN	I-NP	O
SYSTEM	SYSTEM	NN	I-NP	O
:	:	:	O	O
Heart	Heart	NN	B-NP	O
:	:	:	O	O
Ischemia	Ischemia	NN	B-NP	O
:	:	:	O	O
She	She	PRP	B-NP	O
had	have	VBD	B-VP	O
a	a	DT	B-NP	O
negative	negative	JJ	I-NP	O
MIBI	MIBI	NNP	I-NP	O
and	and	CC	O	O
her	her	PRP$	B-NP	O
A	A	NN	I-NP	O
and	and	CC	I-NP	O
B	B	NN	I-NP	O
sets	set	NNS	I-NP	O
of	of	IN	B-PP	O
troponins	troponin	NNS	B-NP	B-protein
were	be	VBD	B-VP	O
negative	negative	JJ	B-ADJP	O
,	,	,	O	O
however	however	RB	B-ADVP	O
her	her	PRP$	B-NP	O
C	C	NN	I-NP	O
set	set	NN	I-NP	O
was	be	VBD	B-VP	O
0.14	0.14	CD	B-NP	O
,	,	,	O	O
which	which	WDT	B-NP	O
was	be	VBD	B-VP	O
thought	think	VBN	I-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
an	an	DT	B-NP	O
error	error	NN	I-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
aspirin	aspirin	NN	I-NP	O
and	and	CC	I-NP	O
statin	statin	NN	I-NP	O
were	be	VBD	B-VP	O
continued	continue	VBN	I-VP	O
.	.	.	O	O

Pump	Pump	NN	B-NP	O
:	:	:	O	O
Her	Her	PRP$	B-NP	O
EF	EF	NN	I-NP	B-protein
was	be	VBD	B-VP	O
35	35	CD	B-NP	O
%	%	NN	I-NP	O
to	to	TO	I-NP	O
40	40	CD	I-NP	O
%	%	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
kept	keep	VBN	I-VP	O
on	on	IN	B-PP	O
hydralazine	hydralazine	NN	B-NP	O
,	,	,	O	O
Lasix	Lasix	NN	B-NP	O
,	,	,	O	O
and	and	CC	O	O
beta-blocker	beta-blocker	NN	B-NP	O
,	,	,	O	O
and	and	CC	O	O
her	her	PRP$	B-NP	O
digoxin	digoxin	NN	I-NP	O
was	be	VBD	B-VP	O
stopped	stop	VBN	I-VP	O
due	due	JJ	B-ADJP	O
to	to	TO	B-PP	O
bradycardia	bradycardia	NN	B-NP	O
during	during	IN	B-PP	O
this	this	DT	B-NP	O
admission	admission	NN	I-NP	O
.	.	.	O	O

In	In	IN	B-PP	O
terms	term	NNS	B-NP	O
of	of	IN	B-PP	O
her	her	PRP$	B-NP	O
valves	valve	NNS	I-NP	O
,	,	,	O	O
she	she	PRP	B-NP	O
has	have	VBZ	B-VP	O
a	a	DT	B-NP	O
St.	St.	NNP	I-NP	O
Jude	Jude	NNP	I-NP	O
valve	valve	VBP	B-VP	O
as	as	RB	B-CONJP	O
well	well	RB	I-CONJP	O
as	as	IN	I-CONJP	O
other	other	JJ	B-NP	O
valve	valve	NN	I-NP	O
abnormalities	abnormality	NNS	I-NP	O
and	and	CC	O	O
her	her	PRP$	B-NP	O
INR	INR	NN	I-NP	O
goal	goal	NN	I-NP	O
was	be	VBD	B-VP	O
2	2	CD	B-NP	O
to	to	TO	B-PP	O
3	3	CD	B-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
taken	take	VBN	I-VP	O
off	off	RP	B-PRT	O
her	her	PRP$	B-NP	O
Coumadin	Coumadin	NN	I-NP	O
for	for	IN	B-PP	O
her	her	PRP$	B-NP	O
stent	stent	JJ	I-NP	O
procedure	procedure	NN	I-NP	O
and	and	CC	O	O
then	then	RB	O	O
bridged	bridge	VBN	B-VP	O
with	with	IN	B-PP	O
heparin	heparin	NN	B-NP	O
for	for	IN	B-PP	O
a	a	DT	B-NP	O
PTT	PTT	NN	I-NP	O
goal	goal	NN	I-NP	O
of	of	IN	B-PP	O
60	60	CD	B-NP	B-DNA
to85	to85	NN	I-NP	I-DNA
.	.	.	O	O

Her	Her	PRP$	B-NP	O
Coumadin	Coumadin	NN	I-NP	O
was	be	VBD	B-VP	O
restarted	restart	VBN	I-VP	O
and	and	CC	O	O
we	we	PRP	B-NP	O
waited	wait	VBD	B-VP	O
until	until	IN	B-SBAR	O
she	she	PRP	B-NP	O
was	be	VBD	B-VP	O
therapeutic	therapeutic	JJ	B-ADJP	O
at	at	IN	B-PP	O
an	an	DT	B-NP	O
INR	INR	NN	I-NP	B-protein
above	above	IN	B-PP	O
2	2	CD	B-NP	O
before	before	IN	B-SBAR	O
she	she	PRP	B-NP	O
was	be	VBD	B-VP	O
discharged	discharge	VBN	I-VP	O
.	.	.	O	O

Rate	Rate	NN	B-NP	O
:	:	:	O	O
She	She	PRP	B-NP	O
is	be	VBZ	B-VP	O
normally	normally	RB	B-ADVP	O
in	in	IN	B-PP	O
atrial	atrial	JJ	B-NP	O
fibrillation	fibrillation	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
developed	develop	VBD	B-VP	O
bradycardia	bradycardia	NN	B-NP	O
for	for	IN	B-PP	O
several	several	JJ	B-NP	O
days	day	NNS	I-NP	O
,	,	,	O	O
which	which	WDT	B-NP	O
was	be	VBD	B-VP	O
though	though	IN	B-SBAR	O
to	to	TO	B-VP	O
be	be	VB	I-VP	O
a	a	DT	B-NP	O
combination	combination	NN	I-NP	O
of	of	IN	B-PP	O
some	some	DT	B-NP	O
Lopressor	Lopressor	NN	I-NP	O
given	give	VBN	B-VP	O
to	to	TO	B-PP	O
her	her	PRP	B-NP	O
in	in	IN	B-PP	O
ED	ED	VBN	B-VP	O
when	when	WRB	B-ADVP	O
she	she	PRP	B-NP	O
was	be	VBD	B-VP	O
having	have	VBG	I-VP	O
her	her	PRP$	B-NP	O
rule	rule	NN	I-NP	O
out	out	IN	B-PP	O
as	as	RB	B-CONJP	O
well	well	RB	I-CONJP	O
as	as	IN	I-CONJP	O
slightly	slightly	RB	B-NP	O
elevated	elevated	JJ	I-NP	O
levels	level	NNS	I-NP	O
of	of	IN	B-PP	O
digoxin	digoxin	NN	B-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
dioxin	dioxin	NN	I-NP	O
was	be	VBD	B-VP	O
stopped	stop	VBN	I-VP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
beta-blocker	beta-blocker	NN	I-NP	O
was	be	VBD	B-VP	O
stopped	stop	VBN	I-VP	O
and	and	CC	O	O
then	then	RB	B-VP	O
restarted	restart	VBD	I-VP	O
at	at	IN	B-PP	O
a	a	DT	B-NP	O
lower	low	JJR	I-NP	O
dose	dose	NN	I-NP	O
.	.	.	O	O

By	By	IN	B-PP	O
discharge	discharge	NN	B-NP	O
,	,	,	O	O
she	she	PRP	B-NP	O
was	be	VBD	B-VP	O
tolerating	tolerate	VBG	I-VP	O
low-dose	low-dose	JJ	B-NP	O
Lopressor	Lopressor	NN	I-NP	O
.	.	.	O	O

During	During	IN	B-PP	O
the	the	DT	B-NP	O
hospital	hospital	NN	I-NP	O
stay	stay	NN	I-NP	O
,	,	,	O	O
on	on	IN	B-PP	O
2/29/05	2/29/05	CD	B-NP	O
she	she	PRP	B-NP	O
had	have	VBD	B-VP	O
10	10	CD	B-NP	O
beats	beat	NNS	I-NP	O
of	of	IN	B-PP	O
VT	VT	NN	B-NP	O
during	during	IN	B-PP	O
which	which	WDT	B-NP	O
she	she	PRP	B-NP	O
was	be	VBD	B-VP	O
asymptomatic	asymptomatic	JJ	B-ADJP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
blood	blood	NN	I-NP	O
pressure	pressure	NN	I-NP	O
was	be	VBD	B-VP	O
stable	stable	JJ	B-ADJP	O
.	.	.	O	O

Renal	Renal	JJ	B-ADJP	O
:	:	:	O	O
She	She	PRP	B-NP	O
had	have	VBD	B-VP	O
acute	acute	JJ	B-NP	O
renal	renal	JJ	I-NP	O
failure	failure	NN	I-NP	O
on	on	IN	B-PP	O
admission	admission	NN	B-NP	O
and	and	CC	O	O
as	as	IN	B-SBAR	O
I	I	PRP	B-NP	O
had	have	VBD	B-VP	O
dictated	dictate	VBN	I-VP	O
previously	previously	RB	B-ADVP	O
she	she	PRP	B-NP	O
had	have	VBD	B-VP	O
a	a	DT	B-NP	O
ureteral	ureteral	JJ	I-NP	O
stent	stent	NN	I-NP	O
placed	place	VBN	B-VP	O
on	on	IN	B-PP	O
2/29/05	2/29/05	CD	B-NP	O
and	and	CC	O	O
that	that	DT	B-NP	O
was	be	VBD	B-VP	O
then	then	RB	I-VP	O
removed	remove	VBN	I-VP	O
on	on	IN	B-PP	O
2/24/05	2/24/05	CD	B-NP	O
because	because	IN	B-PP	O
of	of	IN	I-PP	O
her	her	PRP$	B-NP	O
severe	severe	JJ	I-NP	O
pain	pain	NN	I-NP	O
.	.	.	O	O

Endocrine	Endocrine	JJ	B-ADJP	O
:	:	:	O	O
She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
kept	keep	VBN	I-VP	O
on	on	IN	B-PP	O
her	her	PRP$	B-NP	O
Levoxyl	Levoxyl	NN	I-NP	O
.	.	.	O	O

Heme	Heme	NNP	B-NP	B-protein
:	:	:	O	O
She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
guaiac	guaiac	JJ	B-NP	O
positive	positive	JJ	I-NP	O
,	,	,	O	O
and	and	CC	O	O
her	her	PRP$	B-NP	O
stools	stool	NNS	I-NP	O
were	be	VBD	B-VP	O
guaiaced	guaiace	VBN	I-VP	O
and	and	CC	O	O
her	her	PRP$	B-NP	O
hematocrit	hematocrit	NN	I-NP	O
was	be	VBD	B-VP	O
monitored	monitor	VBN	I-VP	O
.	.	.	O	O

Although	Although	IN	B-SBAR	O
it	it	PRP	B-NP	O
dropped	drop	VBD	B-VP	O
initially	initially	RB	B-ADVP	O
,	,	,	O	O
it	it	PRP	B-NP	O
did	do	VBD	B-VP	O
not	not	RB	I-VP	O
drop	drop	VB	I-VP	O
further	further	RBR	B-ADVP	O
during	during	IN	B-PP	O
the	the	DT	B-NP	O
hospital	hospital	NN	I-NP	O
stay	stay	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
kept	keep	VBN	I-VP	O
on	on	IN	B-PP	O
her	her	PRP$	B-NP	O
home	home	NN	I-NP	O
pain	pain	NN	I-NP	O
control	control	NN	I-NP	O
medications	medication	NNS	I-NP	O
and	and	CC	O	O
she	she	PRP	B-NP	O
required	require	VBD	B-VP	O
additional	additional	JJ	B-NP	O
pain	pain	NN	I-NP	O
medications	medication	NNS	I-NP	O
when	when	WRB	B-ADVP	O
she	she	PRP	B-NP	O
had	have	VBD	B-VP	O
her	her	PRP$	B-NP	O
stent	stent	NN	I-NP	O
placed	place	VBN	B-VP	O
.	.	.	O	O

Psych	Psych	NN	B-NP	O
:	:	:	O	O
She	She	PRP	B-NP	O
continued	continue	VBD	B-VP	O
her	her	PRP$	B-NP	O
home	home	NN	I-NP	O
medications	medication	NNS	I-NP	O
.	.	.	O	O

GI	GI	LS	B-LST	O
:	:	:	O	O
She	She	PRP	B-NP	O
stayed	stay	VBD	B-VP	O
on	on	IN	B-PP	O
her	her	PRP$	B-NP	O
lactulose	lactulose	NN	I-NP	O
and	and	CC	I-NP	O
Colace	Colace	NN	I-NP	O
and	and	CC	I-NP	O
bowel	bowel	NN	I-NP	O
regimen	regimen	NN	I-NP	O
was	be	VBD	B-VP	O
titrated	titrate	VBN	I-VP	O
to	to	TO	I-VP	O
bout	bout	VB	I-VP	O
BM	BM	NNP	B-NP	O
's	's	POS	B-NP	O
.	.	.	O	O

DISPOSITION	DISPOSITION	NN	B-NP	O
:	:	:	O	O
She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
stable	stable	JJ	B-ADJP	O
on	on	IN	B-PP	O
the	the	DT	B-NP	O
day	day	NN	I-NP	O
of	of	IN	B-PP	O
discharge	discharge	NN	B-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
discharged	discharge	VBN	I-VP	O
to	to	TO	B-PP	O
home	home	NN	B-NP	O
,	,	,	O	O
I	I	PRP	B-NP	O
believe	believe	VBP	B-VP	O
,	,	,	O	O
with	with	IN	B-PP	O
VNA	VNA	NN	B-NP	B-protein
.	.	.	O	O

DISCHARGE	DISCHARGE	NN	B-NP	O
MEDICATIONS	MEDICATIONS	NNS	I-NP	O
:	:	:	O	O
Her	Her	PRP$	B-NP	O
medications	medication	NNS	I-NP	O
on	on	IN	B-PP	O
the	the	DT	B-NP	O
day	day	NN	I-NP	O
of	of	IN	B-PP	O
discharge	discharge	NN	B-NP	O
were	be	VBD	B-VP	O
Coumadin	Coumadin	NN	B-NP	O
6	6	CD	I-NP	O
q.p.m.	q.p.m.	NN	I-NP	O
,	,	,	O	O
hydralazine	hydralazine	NN	B-NP	O
25	25	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	B-ADVP	O
t.i.d.	t.i.d.	FW	I-ADVP	O
,	,	,	O	O
Lasix	Lasix	NNP	B-NP	O
20	20	CD	I-NP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
morning	morning	NN	I-NP	O
and	and	CC	I-NP	O
40	40	CD	I-NP	O
at	at	IN	B-PP	O
night	night	NN	B-NP	O
,	,	,	O	O
Lopressor	Lopressor	NN	B-NP	O
12.5	12.5	CD	I-NP	O
t.i.d.	t.i.d.	NN	I-NP	O
,	,	,	O	O
Aranesp	Aranesp	NN	B-NP	B-protein
100	100	CD	I-NP	I-protein
subcutaneous	subcutaneous	JJ	I-NP	I-protein
q.	q.	NN	I-NP	I-protein
week	week	NN	I-NP	I-protein
,	,	,	O	O
OxyContin	OxyContin	NN	B-NP	O
90	90	CD	I-NP	O
q.	q.	NN	I-NP	O
12h	12h	NN	I-NP	O
.	.	.	O	O

and	and	CC	O	O
40	40	CD	B-NP	O
q.	q.	NN	I-NP	O
2	2	CD	I-NP	O
.	.	.	O	O

p.m.	p.m.	RB	B-ADVP	O
,	,	,	O	O
Nexium	Nexium	NN	B-NP	O
40	40	CD	I-NP	O
daily	daily	RB	B-ADVP	O
,	,	,	O	O
Zocor	Zocor	NNP	B-NP	O
20	20	CD	I-NP	O
mg	mg	NN	I-NP	O
at	at	IN	B-PP	O
bedtime	bedtime	NN	B-NP	O
,	,	,	O	O
aspirin	aspirin	NN	B-NP	O
81	81	CD	I-NP	O
,	,	,	O	O
Colace	Colace	NNP	B-NP	O
100	100	CD	I-NP	O
,	,	,	O	O
Niferex	Niferex	NNP	B-NP	O
150	150	CD	I-NP	O
,	,	,	O	O
Levoxyl	Levoxyl	NNP	B-NP	O
88	88	CD	I-NP	O
,	,	,	O	O
Senna	Senna	NNP	B-NP	O
daily	daily	RB	B-ADVP	O
,	,	,	O	O
and	and	CC	O	O
exemestane	exemestane	NN	B-NP	O
25	25	CD	I-NP	O
mg	mg	NN	I-NP	O
po	po	RB	B-ADVP	O
daily	daily	RB	I-ADVP	O
.	.	.	O	O

FOLLOWUP	FOLLOWUP	NN	B-NP	O
:	:	:	O	O
She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
instructed	instruct	VBN	I-VP	O
to	to	TO	I-VP	O
follow	follow	VB	I-VP	O
up	up	RP	B-PRT	O
with	with	IN	B-PP	O
her	her	PRP$	B-NP	O
PCP	PCP	NN	I-NP	B-protein
.	.	.	O	O

eScription	eScription	NN	B-NP	O
document	document	NN	I-NP	O
:	:	:	O	O
5-0882487	5-0882487	CD	B-NP	O
IS	IS	NNP	I-NP	O
Dictated	Dictated	NNP	I-NP	O
By	By	NNP	I-NP	O
:	:	:	O	O
CONTI	CONTI	NNP	B-NP	O
,	,	,	O	O
RUEBEN	RUEBEN	NNP	B-NP	O
Attending	Attending	NNP	I-NP	O
:	:	:	O	O
SNELLINGS	SNELLINGS	NNP	B-NP	O
,	,	,	O	O
GUADALUPE	GUADALUPE	NNP	B-NP	O
Dictation	Dictation	NNP	I-NP	O
ID	ID	NNP	I-NP	O
6614024	6614024	CD	I-NP	O
D	D	NNP	I-NP	O
:	:	:	O	O
5/24/05	5/24/05	CD	B-NP	O
T	T	NN	I-NP	O
:	:	:	O	O
5/24/05	5/24/05	CD	B-NP	O

